The European Medicines Agency (EMA) has approved the Moderna vaccine against Covid-19, it became known a while ago.
Following the green light from Coreper, the final stage is the approval by the European Commission, which is expected to follow soon. “The EMA recommends that the conditional marketing authorization of the Moderna Covid-19 vaccine be granted in order to prevent the disease in people over the age of 18,” said a press release from the Amsterdam-based European Medicines Agency.
“Good news for our efforts to bring more Covid-19 vaccines to Europeans,” said Commission President Ursula von der Leyen . “The European Medicines Agency has found that the Moderna vaccine is safe and effective. “We are now working at full speed to get it approved and made available to the EU,” she added in a Twitter post.
There had been intense pressure from Berlin on EMA for the speedy approval of this vaccine as well, following strong criticism of the problems, delays and shortcomings that have arisen in many EU countries. This is the second vaccine against Covid-19 approved by EMA, following that of BioNTech / Pfizer on 21 December, for which the Commission soon gave the green light and was to date the only one approved in Europe. where vaccination campaigns began on 27 December. The vaccine has already been approved by the United States for emergency use in people over the age of 18 on December 18 and five 24 hours later by Canada, while last Monday it was approved by Israel.
Adoption of the second vaccine will boost vaccination campaigns in European Union countries, far behind the United States, Britain or Israel. The President of the European Council Charles Michel announced before the end of January, an extraordinary Session, via video conference, which will be dedicated to the health crisis. In a press conference from Lisbon, on the occasion of the start of Portugal’s rotating presidency on 1 January, Michel referred to the “enormous challenge” posed by the development of these vaccines for a population of 450 million people: “The European Commission, “With the support of the Member States, it is working day and night to ensure that we can increase the number of vaccines available,” while ensuring “respect for the independence of the drug body”, he stressed.
94% effective Moderna vaccine does not require dry ice storage, like that of BioNTech / Pfizer, but is said to be more expensive than what the EU ordered, as the dose is around € 18, well over € 12 for the vaccine. BioNTech / Pfizer and the ten of CureVac. That may be why the Commission ordered fewer doses – 180 million vs. 300 million for Pfizer and 225 million for Curevac – with the option of buying another 180 million. But even if the Commission had ordered more doses, Moderna has limited production capacity in the EU and, as he said, could produce up to 20 million doses – all for the US. Moderna now says it can prepare between 500 and 600 million doses by the end of 2021 for worldwide distribution, it is unknown how many of them are destined for the EU.
Source – iefimerida.gr